Subscribe To

Price Alert Latest News Economic Calendar News

HEPA / Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference

EDISON, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that its Chief Executive Officer, Robert Foster, PharmD, PhD, will participate in a panel discussion during the 2023 Cantor Global Healthcare Conference on Wednesday, September 27, 2023 at 9:45 a.m. ET in NYC. Read More

Demo Live Account See Partner Details

Content Topics

Hepion

Pharmaceuticals

Participate

2023

Cantor

Global

Healthcare

Conference

Stock

HEPA

Posted: Sep 21 2023, 16:05

Author Name: GlobeNewsWire

HEPA News

By GlobeNewsWire
September 21, 2023

Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference

EDISON, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Art

By GlobeNewsWire
June 15, 2023

Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023

- Preclinical studies demonstrate rencofilstat may protect against NASH/NAFLD, shift the liver transcriptome and lipidome toward NASH resolution –

By Zacks Investment Research
May 24, 2023

Here's Why Hepion Pharma (HEPA) is Up More Than 80% in Two Days

Hepion Pharmaceuticals' (HEPA) lead pipeline candidate, rencofilstat, demonstrates improvements in physiologic liver function and key NASH biomarkers

By Invezz
May 23, 2023

HEPA stock price surged but beware of this glaring Hepion risk

Hepion Pharmaceuticals' (NASDAQ: HEPA) stock price went parabolic on Monday after the company made an important announcement about its mid-stage trial

By InvestorPlace
May 22, 2023

Why Is Hepion Pharmaceuticals (HEPA) Stock Up 68% Today?

Hepion Pharmaceuticals (NASDAQ: HEPA ) stock is rising higher on Monday as the company prepares to cover clinical trial results. Hepion Pharmaceutica

By GlobeNewsWire
May 19, 2023

Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ‘ALTITUDE-NASH' Liver Function Trial of Rencofilstat

EDISON, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artif

By GlobeNewsWire
June 15, 2022

Hepion Pharmaceuticals to Present Five Posters at EASL International Liver Congress™ 2022

- Hepion Represented as Authors in Preclinical and Clinical Posters Related to Rencofilstat and Cyclophilins –

By Zacks Investment Research
March 23, 2022

Is Hepion Pharmaceuticals, Inc. (HEPA) Stock Outpacing Its Medical Peers This Year?

Here is how Hepion Pharmaceuticals, Inc. (HEPA) and ICU Medical (ICUI) have performed compared to their sector so far this year.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.